Pedro Barata, MD, MSc, FACP, discussessequencing for a relapsed/refractory metastatic renal cell carcinoma patient case. He also discusses how third-line mRCC therapy aims for disease control and symptom palliation with careful toxicity management. Options include cabozantinib, lenvatinib/everolimus, and tivozanib, with selection based on prior therapy, comorbidities, and tolerability.
Amit Mahipal, MD, discusses the patient case of a 57-year-old woman diagnosed with advanced unresectable hepatocellular carcinoma (uHCC). He also discusses how first-line systemic therapy for advanced uHCC focuses on tyrosine kinase inhibitors (lenvatinib, sorafenib), considering patient factors, monitoring response depth, managing adverse events, and balancing efficacy with quality of life.
Amit G. Singal, MD, MS discusses the case of a 60-year-old man with intermediate/advanced unresectable hepatocellular carcinoma that requires careful treatment planning because of his age, disease stage, and potential therapeutic approaches, including systemic therapies and locoregional interventions.
An expert discusses the latest advancements in the use of androgen receptor inhibitors (ARIs) and radium-223 (Ra-223) for the treatment of metastatic castration-resistant prostate cancer, highlighting their evolving roles in improving patient outcomes.
Sumanta K. Pal, MD, provides comprehensive insights into second-line RCC treatment approaches, discussing the evolution from first-line therapy goals, analyzing key clinical trial data (including CONTACT-03 and TiNivo-2), evaluating patient-reported outcomes, explaining individualized therapy selection factors, addressing sequencing strategies across multiple lines of treatment, offering practical guidance on adverse event management, and highlighting promising future research directions in the field.
Misako Nagasaka, MD, PhD discusses a patient case involving a 47-Year-Old Woman with EGFR-mutated Advanced/Metastatic NSCLC and discusses optimizing 1L EGFR-mutant NSCLC care requires balancing efficacy and toxicity in combination therapies. She also reviews MARIPOSA/FLAURA2 data inform sequencing, AE management, resistance testing, and future innovations.
Amrita Krishnan, MD, discusses the evolving treatment landscape for early relapsed/refractory multiple myeloma, focusing on CAR T-cell therapy selection, sequencing, and management. Key areas covered include KarMMa-3 trial data for ide-cel, real-world evidence, toxicity management, community practice strategies, and emerging therapeutic approaches. Emphasis is placed on optimal patient care from selection through long-term monitoring, with consideration of novel combinations and future directions.
Aimee Merino, MD, discusses the management of a 60-year-old patient with early relapse/refractory multiple myeloma and highlights the importance of identifying high-risk disease, the referral process for chimeric antigen receptor T-cell therapy, and the latest efficacy outcomes from the CARTITUDE-4 trial while also addressing emerging treatment strategies and challenges in managing relapsed/refractory multiple myeloma.
Evan Y. Yu, MD, discusses how advances in androgen receptor inhibitors (ARIs) and emerging clinical trial data are shaping personalized treatment strategies for in metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC).
Binod Dhakal, MD, discusses a clinical presentation of a 72-year-old man, previously diagnosed with relapsed/refractory multiple myeloma. He discusses the evolution of the treatment landscape including the role of bispecific T-cell engagers (BiTEs), data updates from the MonumenTAL-1 study, cytokine release syndrome (CRS), step-up dosing (SUD) and initial challenges when using talquetamab in this setting, and the future of relapsed/refractory multiple myeloma treatment.
Ticiana Leal, MD, discusses how emerging targeted therapies for small cell lung cancer are reshaping treatment strategies and improving patient outcomes, particularly in extensive-stage disease.
Panelists discuss advances in targeted therapy for small cell lung cancer (SCLC), focusing on the impact of recently approved therapies on survival benefits, the mechanisms of DLL3-directed bispecifics, and the integration of these therapies into updated NCCN guidelines for extensive stage SCLC.
Solly Chedid, MD, presents a case of a patient with lower-risk MDS and provides clinical insights on the first-line use of an erythroid maturating agent.
Jamie L. Koprivnikar, MD, presents a case of a 70-year-old patient with lower-risk MDS and provides detailed insights on clinical research and the evolving treatment landscape.
Abdulraheem Yacoub, MD discusses treatment strategies, emerging therapies, and clinical evidence for managing ESA-ineligible, transfusion-dependent lower risk myelodysplastic syndrome patients, with a focus on the novel telomerase inhibitor imetelstat, as well as treatment strategies and emerging therapies for LR MDS patients with transfusion-dependent anemia who are refractory to ESAs, particularly those who are RS+.
Dr. Mikkael Skeres, MD, shares his thoughts and experience with Imetelstat, a first in class telomerase inhibitor for use in patients with lower-risk Myelodysplastic syndromes.
Caitlin Costello, MD, presents the case of a 60-year-old woman with later relapsed/refractory multiple myeloma and provides comprehensive insights on treatment practices and the evolving therapeutic landscape.
Chris Benton, MD, presents a patient case and provides clinical insights on the use of luspatercept, an erythroid maturating agent, in patients with lower-risk myelodysplastic syndromes.
Sham Mailankody, MBBS, presents the case of a patient with early relapse/refractory multiple myeloma and addresses the evolving treatment landscape, highlighting therapeutic options, clinical trial data, recent approvals, and adverse event management practices.
A key opinion leader presents a comprehensive case study of a 73-year-old patient diagnosed with metastatic urothelial carcinoma (mUC), delving into various lines of treatment, strategies for managing adverse events, and the importance of testing specific biomarkers to guide personalized therapy decisions.
Dr. Bose discusses the case of a 68-year-old woman with intermediate-2 risk myelofibrosis, including diagnostic findings, treatment selection based on guidelines, and goals of therapy. He reviews the impact of ruxolitinib on overall survival from the COMFORT trials and provides guidance on dosing, adverse effect management, and the role of emerging therapies. Dr. Bose also covers strategies for managing anemia in myelofibrosis patients on ruxolitinib. The REALISE trial implications for ruxolitinib dosing strategy are discussed.
Dr Neal Shore shares his clinical perspectives and insights on the management of patients with mHSPC. With his extensive expertise, Dr Shore will delve into initial therapy considerations, emerging data on combination regimens, potential adverse events, and the future landscape of mHSPC treatment. This comprehensive overview will produce valuable insights for healthcare professionals seeking to optimize care for their patients with this challenging condition.
Anne P. O’Dea, MD, presents the case of a 49-year-old woman with HR+/HER2- metastatic breast cancer, discusses the EMERALD trial, and provide clinical insights on treatment considerations and decisions.
Dr. Kuykendall discusses the case of a 67-year-old man with advanced polycythemia vera (PV) factors impacting selecting and sequencing of treatments like hydroxyurea, ruxolitinib, interferons, and emerging therapies.
Dr. Bose discusses the case of a 68-year-old woman with intermediate-risk myelofibrosis, including his initial impressions of the case, the key factors he considers when selecting initial therapy, and his perspective on the efficacy and safety of JAK inhibitors based on clinical trial data. He also covers timing of ruxolitinib initiation, managing anemia in patients on ruxolitinib, preserving quality of life, and the unmet needs and emerging therapies in the management of intermediate myelofibrosis.
Yi-Bin Chen, MD, presents an overview of graft versus host disease (GVHD), covering a patient case, first-line and second-line treatment options, associated toxicities, and the potential impact of ongoing clinical trials on the future of GVHD treatment.
Dr. Schiller discusses the management of elderly transplant-ineligible patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), including an overview of the key clinical and pathologic features, the factors that make this patient population difficult to treat, and the limitations and potential future improvements in BPDCN treatments for this specific population.
Expert perspectives on the management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) from a case-based peer discussion. The segments cover an overview of BPDCN, including clinical hallmarks and diagnostic challenges, as well as the appropriateness of initial therapy with tagraxofusp based on NCCN guidelines. The discussion explores the mechanism of action and potential efficacy of tagraxofusp, recent clinical trial data like the CADENZA study, and the potential of anti-CD123 CAR T-cell therapy for BPDCN. The segments also evaluate strategies for monitoring and mitigating adverse events, particularly capillary leak syndrome, quality of life considerations with various BPDCN treatments, and the future landscape with emerging research and limitations of current options, featuring insights from Dr. James K. McCloskey II.
Dr. Cutler discusses the management of chronic graft-versus-host disease (cGvHD) in a 48-year-old man who developed cGvHD after undergoing a matched unrelated donor (MUD) hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML), despite receiving tacrolimus and methotrexate as prophylaxis.